VT WT1
Alternative Names: VT-WT1; VT-WT1-A; VT-WT1-L; WT1- specific cytotoxic T lymphocytesLatest Information Update: 28 Oct 2022
At a glance
- Originator ViGenCell
- Developer Catholic University of Korea; ViGenCell
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Lung cancer; Myelodysplastic syndromes
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Lung-cancer in South Korea (IV, Infusion)
- 28 Apr 2020 No recent reports of development identified for clinical-Phase-Unknown development in Myelodysplastic-syndromes(Recurrent) in South Korea (IV, Infusion)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Recurrent) in South Korea (IV, Infusion)